01—Abstract
Summary
Summary of the 8-K filed May 7, 2024. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported first quarter 2024 results on May 7, 2024, as furnished in Exhibit 99.1 under Item 2.02.
Total revenues were $195.9 milliona, up from $162.1 million in the first quarter of 2023, driven by royalty revenue of $120.6 million and higher milestone revenue. Net income was $76.8 million, or $0.60 GAAP diluted EPS, compared with $39.6 million, or $0.29, a year earlier. Non-GAAP diluted EPS was $0.79 versus $0.47, and EBITDA and Adjusted EBITDA were both $115.7 million versus $74.3 million.
The company reiterated its 2024 guidance: total revenue of $915 million to $985 millionb, royalty revenue of $500 million to $525 million, Adjusted EBITDA of $535 million to $585 million, and Non-GAAP diluted EPS of $3.55 to $3.90. Cash, cash equivalents and marketable securities were $463.5 million at March 31, 2024, up from $336.0 million at December 31, 2023, which the company attributed primarily to cash generated from operations. Total stockholders' equity rose to $177.8 million from $83.8 million.
Management highlighted partner milestones, including FDA acceptance of Bristol Myers Squibb's subcutaneous nivolumab with a PDUFA goal date of February 28, 2025 and a $15.0 millionc milestone payment, and argenx's VYVDURA approval in Japan with $14.0 million in total milestone payments. The company also referenced a $750 million share repurchase program announced in February 2024.
02—Key points
Key Highlights
- Total revenues of $195.9 million in Q1 2024 versus $162.1 million in Q1 2023, a 21% year-over-year increase.
- Royalty revenue of $120.6 million, up 21% from $99.6 million, mainly from subcutaneous DARZALEX and Phesgo.
- GAAP net income of $76.8 million and GAAP diluted EPS of $0.60, versus $39.6 million and $0.29 a year earlier.
- Operating income of $95.5 million, up from $53.8 million, as cost of sales fell to $28.3 million from $35.2 million.
- 2024 guidance reiterated: total revenue $915–$985 million, Adjusted EBITDA $535–$585 million, Non-GAAP diluted EPS $3.55–$3.90.
- Cash, cash equivalents and marketable securities rose to $463.5 million from $336.0 million at December 31, 2023.
- Partner milestones include a $15.0 million payment tied to FDA acceptance of BMS's subcutaneous Opdivo, and $14.0 million in milestones tied to VYVDURA's availability in Japan.
03—Questions
Frequently Asked Questions
How did Halozyme perform in the first quarter of 2024?
Total revenues rose 21% to $195.9 million, net income was $76.8 million, and GAAP diluted EPS was $0.60. Growth was driven mainly by royalty revenue and higher milestone revenue, and operating income increased to $95.5 million from $53.8 million.
Did Halozyme change its 2024 financial guidance?
No. The company reiterated the guidance first given on January 17, 2024: total revenue of $915 million to $985 million, royalty revenue of $500 million to $525 million, Adjusted EBITDA of $535 million to $585 million, and Non-GAAP diluted EPS of $3.55 to $3.90. EPS guidance does not consider potential future share repurchases.
What drove the increase in royalty revenue?
Royalty revenue was $120.6 million, up from $99.6 million, primarily due to increases in revenue from subcutaneous DARZALEX and Phesgo, according to the filing.
What is the status of the share repurchase program?
In February 2024, the company announced its third share repurchase program to buy back up to $750 million of its outstanding common stock. The press release lists it as a recent corporate highlight.
What upcoming regulatory events did the company highlight?
The company cited a PDUFA goal date of February 28, 2025 for BMS's subcutaneous nivolumab, a PDUFA action date of June 21, 2024 for VYVGART Hytrulo in CIDP, and potential U.S. approval of Roche's Tecentriq SC in September 2024 and ocrelizumab SC in September 2024.
04—Continue